What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage of…
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers? Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the…
Can Targeting Patient Subpopulations Serve as a Market Access Lever? The asthma market is dominated by a number of effective and well-established treatments, including inhaled and oral therapies,…
How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market? Affecting more than 40 million people in its severe form, dry eye disease represents a large,…
As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition,…
Developing a biosimilar requires considerable investment and expertise. In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that…
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75% of…
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics that…
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on renal anemia…
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of…
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market? Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and…
What Does This Emerging Trend Hold for Branded Agents? Asthma and chronic obstructive pulmonary disease (COPD) are chronic diseases of the airways affecting millions of Americans and representing…
